Skip to main content
MedPathMedPath Home
Clinical Trials/ACTRN12622000038796
ACTRN12622000038796
Recruiting
未知

Pharmacogenomics guided antiplatelet selection strategy prior to intracranial or carotid stenting: investigating the impact on platelet aggregation at time of surgery

Royal North Shore Hospital0 sites80 target enrollmentJanuary 17, 2022
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Royal North Shore Hospital
Enrollment
80
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
January 17, 2022
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • •Patient who are candidates for stenting.
  • •Patients who are able to comply with dual antiplatelet therapy
  • •Patients are willing to give informed written consent.
  • •Patients aged 18 or older will be eligible.

Exclusion Criteria

  • •Contraindications to antiplatelet treatment including but not limited to listed below
  • •Acute or ongoing bleeding
  • •Thrombocytopenia ie. platelets \< 50,000 per microL
  • •Severe liver disease as determined by the treating physician
  • •Renal Failure eGFR \< 30 ml/min/1\.73m2
  • •Inability to comply with follow up visits.
  • •Concurrent requirement for anticoagulation with warfarin or a NOAC
  • •TPA use within the last 24 hours

Outcomes

Primary Outcomes

Not specified

Similar Trials

Terminated
Phase 4
Pharmacogenomics of Anti-platelet Intervention-2 (PAPI-2) StudyCardiovascular DiseasesAcute Coronary Syndrome
NCT01452152University of Maryland, Baltimore9
Active, not recruiting
Not Applicable
Precision PCI RegistryCoronary Artery DiseasePercutaneous Coronary Intervention
NCT06143709University of Florida1,643
Terminated
Phase 4
Antiplatelet Therapy Guided by Thrombelastography in Patients With Acute Coronary Syndromes (TEGCOR Study)ThrombosisCoronary Artery Disease
NCT01612884Indiana University67
Completed
Phase 4
Pharmacogenomics of Antiplatelet ResponseAtherosclerosis
NCT02234427Johns Hopkins University34
Completed
Phase 4
Determining Genetic Role in Treatment Response to Anti-Platelet Interventions (The PAPI Study)Platelet Aggregation InhibitorsCoronary Heart Disease
NCT00799396University of Maryland, Baltimore682